Challenges, Benefits Of Device Interoperability Standards Explored at AAMI-FDA Summit
This article was originally published in The Gray Sheet
The challenges and benefits of interoperability – getting devices to electronically interact with each other and with health information technology systems to improve patient care – were explored at the Oct. 2-3 AAMI-FDA Interoperability Summit in Herndon, Va.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.